Oral Intradialytic Amino Acid Supplementation to Vitalize End-stage Kidney Disease Patients on Hemodialysis

Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-64
SponsorThe University of Texas Health Science Center at San Antonio

About this trial

The study will test and compare the efficacy of a single essential amino acid valine with a combination of essential amino acids (EAA) supplement on fatigue, frailty, and cognitive function in end-stage kidney disease (ESKD) patients undergoing hemodialysis (HD) treatment.

Eligibility criteria

Qualifiers

Male or Female

Age 18-64 years

Receiving 3 x weekly in clinic hemodialysis for at least 6 months

Disqualifiers

Hypersensitivity to amino acid(s) and/or any excipient

Clinical documentation of COVID-19

Concomitant intake of amino acids supplements

Current use or abuse of alcohol, marijuana, narcotic, or other substances

Trial design

Treatments tested in this trial

  • Valine
  • EEA

Treatment groups

28 Participants
are divided into 2 treatment groups

Locations

1
The University of Texas Health Science Center at San Antonio78229, San AntonioTexas, United States

Sponsors and collaborators

The University of Texas Health Science Center at San Antonio

Lead sponsor

National Center for Advancing Translational Sciences (NCATS)

Collaborator

IIMS-UT Health San Antonio

Collaborator